There are similarities between the 2014 formularies and their commercial counterparts. However, differences in the drug benefit designs show the predominance of four to five tiers, higher deductibles and higher copays or coinsurance levels compared to commercial benefits.
A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.
Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.
Healthcare workers seek out health-related information on their own time, and through internet connections other than ones offered by their employers.
The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.
The latest data shows an overall widening of the US.
The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.
Tech site Venturebeat, citing anonymous sources, says doctors are too overwhelmed and weary to evaluate how many steps you took this weekend.
African-American women had the highest risk of being diagnosed with diabetes—55%. Hispanic men and women were close behind, carrying a 50% risk of being diagnosed with diabetes.
A study indicates consumers stop using them at the six-month mark.
Half-measures, like diabetes educational materials without a part B, fared poorly.
The pharma payment verification site has been temporarily shut down by CMS due to incorrect information, ProPublica reported today.
A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.
Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like meals, travel, gifts, consulting and research
Generics made up almost 75% of prescriptions in the United Kingdom last year.
An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.
The rate of decrease in industry's budget for continuing medical education (CME) slowed last year.
Industry reined in commercial support for CME in 2013—the sixth consecutive annual decrease—data released today by the ACCME show.
German healthcare data from 2004 through 2010 across a data set that included 146,000 patients shows dementia surfaced later among Actos patients.
The FDA began its drug review at a median time of 103 days sooner than the EMA. Being first, researchers found, often resulted in quicker approval.
Prices for some generics are rising, thanks to limited competition.
Credit card and loyalty program purchases will help Carolinas HealthCare System flag potential patient behavior issues.
Zogenix is working on a less easily abused formulation of its controversial prescription painkiller.
The Centers of Disease Control reports that prescribers wrote enough painkiller prescriptions to give one bottle to every adult in the US in 2012.
The networking site's emotion experiment rankles some in the science and political communities.
IMS is offering $520 million cash to add Cegedim's CRM and strategic data business. Cegedim says it will use the money to pay down debt.
EvaluatePharma's World Preview 2014 has pharma soaring to new lucrative heights in six years' time, buoyed by biologics and a formidable pipeline.
Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.
Platform lets pharma firms mine big data, and monitor whether millions spent on ad campaigns or medical education are having the desired effect
Gene mutations lead researchers to rethink ways to protect the heart.
An Alzheimer's Association survey finds 59% think the degenerative disease is just part of aging.
Researchers at Montreal's McGill University survey the explosion in prescription painkiller use and abuse.
The drugmaker has told global regulators it failed to share 10,000 reported cases of side effects for a variety of its drugs.
Patients taking a high-dose form of Novo Nordisk diabetes drug Victoza saw an average weight loss of 5.9% of their body weight, data from a study show.
A USA today analysis shows Medicare painkiller prescriptions rose 30% between 2007 and 2012.
Yale researchers find patients are paying more money for newer diabetes medications as they gravitate towards insulin analogs, over human synthetic and animal insulin.
Researchers argue it makes economic sense to employ Value-Based Insurance Design plans for costly specialty medications.
Two studies found two different facets of statin therapy—one found patients moved less a year after starting their regimens, and another that the drugs upped the diabetes risk for some.
Express Scripts said that family and internal medicine doctors were the top opioid prescribers between 2011 and 2012.
A study shows doctors have been giving more political donations—and leaning heavily Democrat—since 1991.
Researchers say switching patients from Lucentis to Avastin eye diseases could save the government $18 billion.
The potential of immunotherapy is great, but the news from the 2014 medical meeting shows that great may not be gargantuan in terms of treatment reach.
The regulator's latest study will use eye-tracking tools.
The regulator is allocating almost $38 million to improve data-guided decision-making.
The pharma market research major is working on unifying into one company with two main product lines, and is also in the process of a re-brand.
The companies announced Tuesday that Arzerra, already indicated for leukemia, failed to outdo Roche's Rituxan in the lymphoma setting.
Both companies revealed Phase-III data for idiopathic pulmonary fibrosis treatments. The progressive disease generally kills patients within three years of diagnosis.
Gelesis is pouring money into its obesity "smart pill," and Novo reports weighty success among subjects taking liraglutide.
The drugmaker announced Wednesday that researchers would be able to access clinical trial data.
GlaxoSmithKline announced Tuesday its Phase-III drug from the Human Genome Sciences acquisition failed to hit its primary endpoint.
Phase-III results for Eli Lilly basal insulin peglispro showed superior blood sugar reduction vs. Sanofi's Lantus in trials, but a number of safety issues could hurt its appeal.
The company announced Monday that researchers will be able to seek out clinical trial data going back to 1998.
An EY report finds that pharma is not only failing to give payers the right type of drug data, but that industry has a lot of trust-building to do before they will accept it.
According to an analysis of final data from one of the WHI's trials, each dollar received results in a net economic value of $140.
Merrimack Pharma said its candidate for pancreatic cancer increased overall survival, and that it plans to file applications in the US and EU this year.
An analysis by Bloomberg today shows why drug pricing "keeps defying the law of gravity."
Sales slipped 1% for the quarter, but the drugmaker couched the financials with news from its much-watched effort in immuno-oncology: that it will wrap its nivolumab filing by the end of this year.
A piece about obesity and Coca-Cola shows the widespread nature of conflict-of-interest discussions and concerns about the sway that honoraria and other goodies may exert on researchers.
A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.
US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.
Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also reaped blockbuster sales for Gilead.
Wednesday's coverage of doctor pay roiled physicians who say the CMS data set oversimplifies payment information and skews reality.
Phase-II results indicate Merck's all-in-one HCV oral could put pressure on Gilead.
Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.
Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.
Phase-III results prompted the drugmaker to pursue a third-quarter filing.
Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.
Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.
The ACA has spurred double-digit increases in demand for pharmaceuticals, new data suggest.
The drugmaker saw positive results in demonstrating LDL reductions in Japanese patient populations.
Detailed Phase-III results from several PCSK9 candidates confirm the clinical ability of the newest class of cholesterol-lowering treatments.
Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.
The company unveiled the mix-and-match marketing management tool at the Eye for Pharma conference in Barcelona.
A rival's late-stage trial results suggest the pain med may have a short market life. The key: an FDA division head's documented willingness to overturn the approval should another pain option surface.
A report of over 270,000 US medical sites signals that EHR adoption is no longer a luxury reserved for hospitals and health systems.
Pfizer hit its endpoints for preventing pneumonia among the elderly, but the data may not be robust enough to spur vaccination.
Express Scripts notes that these prescriptions may not, in fact, be for ADHD.
Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.
A survey of patients found greater prescription drug adherence among patients who received a free 30-day sample in addition to a prescription.
@openFDA and its related website launched February 27.
Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?
The drugmaker says researchers will be able to view patient-level data and promises less jargon-filled summaries by year-end.
The new label will reflect the RA pill's superiority to methotrexate and placebo in inhibiting the progression of structural joint damage.
Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.
The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.
The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.
A report published by JAMA indicated that online reviews sway a percentage of patients, but that personal recommendations hold more weight.
The school will act as an independent panel for the drug maker, reviewing requests from investigators for access to anonymized, clinical-trial data.
The US agency says we've got too much data that cannot be reproduced.
A young company is hoping its analytics platform can help doctors and pharma figure out who's going to stop taking their medication, and get them back on track.
Positive results from a Phase-III trial edge Amgen's evolocumab closer to approval, though it's still behind rivals in the PCSK9 race.
The data and analytics giant is looking to launch an IPO. The company, which is the subject of an antitrust suit, said in its prospectus that it anticipates future acquisitions.
Mid-stage data show the drug, romosozumab, was associated with significant increases in bone mineral density compared to Lilly's Forteo and off-patent Fosamax.
Big Data is coming and with it the danger of pharmaceutical marketers relying on it too heavily
Our year-end list captures the 10 that sparked heaviest interest.
Kalydeco failed to hit its primary endpoint of significantly improving lung function in a subset of CF patients, but some did show a benefit.
Sovaldi is already approved for most patients with HCV, but its marketer may have earned itself some breathing room against rivals in the next stage of the all-oral hep. C arms race.
A recent poll shows a strong desire among web-savvy patients to play a more active role in medical research.
Sanofi top-lined positive clinical data today from its investigational basal insulin, as it seeks to defend its position in this fast-growing segment.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.